Cost of COVID-19 vaccine delivery in nine States in Nigeria via the U.S. Government Initiative for Global Vaccine Access.

Cost of COVID-19 vaccine delivery in nine States in Nigeria via the U.S. Government Initiative for Global Vaccine Access.

Publication date: Oct 14, 2024

In 2022, the U. S. Centers for Disease Control and Prevention collaborated with implementing partners, African Field Epidemiology Network and Sydani Group, to support COVID-19 vaccination efforts in Nigeria. To characterize the costs of COVID-19 vaccination, this study evaluated financial costs per dose for activities implemented to support the intensification campaign for COVID-19 vaccination. This retrospective evaluation collected secondary data from existing expenditure and programmatic records on resource utilization to roll out COVID-19 vaccination during 2022. The study included incremental financial costs of the activities implemented to support an intensification campaign for COVID-19 vaccination across nine states and six administrative levels in Nigeria from the perspective of the external donor (U. S. Government). Costs for vaccines and injection supplies, transport of vaccines, and any economic costs, including government in-kind contributions, were not included. All costs were converted from Nigerian Naira to 2022 U. S. Dollars (US$). The estimated financial delivery cost of the COVID-19 vaccination intensification campaign was US$0. 84 per dose (total expenditure of US$6. 29 million to administer 7,461,971 doses). Most of the financial resources were used for fieldwork activities (86%), followed by monitoring and supervision activities (8%), coordination activities (5%), and training-related activities (1%). Labor (58%) and travel (37%) were the resource inputs that accounted for the majority of the cost, while shares of other resource inputs were marginal (1% for each). Most labor costs (79%) were spent on payments for mass vaccination campaign teams, including pay-for-performance incentives. By administrative level, the largest share of costs (46%) was for pay-for-performance incentives at the community, health facility, or campus levels combined, followed by local government area level (24%), community level only (15%), state level (9%), national level (3%), campus level only (1%), and health facility level only (

Open Access PDF

Concepts Keywords
African Costs
Financial COVID-19
Global Nigeria
Vaccine Vaccine

Semantics

Type Source Name
disease MESH COVID-19
disease IDO facility
pathway REACTOME Reproduction
disease IDO country
disease IDO intervention
drug DRUGBANK Ademetionine
drug DRUGBANK Etoperidone
drug DRUGBANK Coenzyme M
disease MESH emergency
disease MESH measles
pathway KEGG Measles
disease MESH yellow fever
disease MESH meningitis
drug DRUGBANK Trestolone
disease IDO production
disease IDO quality
disease MESH pneumonia
drug DRUGBANK L-Aspartic Acid

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *